DK200000602A - Ny fremgangsåde til behandling - Google Patents
Ny fremgangsåde til behandling Download PDFInfo
- Publication number
- DK200000602A DK200000602A DK200000602A DKPA200000602A DK200000602A DK 200000602 A DK200000602 A DK 200000602A DK 200000602 A DK200000602 A DK 200000602A DK PA200000602 A DKPA200000602 A DK PA200000602A DK 200000602 A DK200000602 A DK 200000602A
- Authority
- DK
- Denmark
- Prior art keywords
- amoxycillin
- potassium clavulanate
- pharmaceutical formulation
- release
- slow release
- Prior art date
Links
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 50
- 229960003022 amoxicillin Drugs 0.000 description 45
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 45
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 description 24
- 239000008194 pharmaceutical composition Substances 0.000 description 18
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000007942 layered tablet Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 150000007524 organic acids Chemical class 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229920001285 xanthan gum Polymers 0.000 description 5
- 239000000230 xanthan gum Substances 0.000 description 4
- 235000010493 xanthan gum Nutrition 0.000 description 4
- 229940082509 xanthan gum Drugs 0.000 description 4
- 239000012736 aqueous medium Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12907499P | 1999-04-13 | 1999-04-13 | |
| US15072799P | 1999-08-25 | 1999-08-25 | |
| US15981399P | 1999-10-15 | 1999-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK200000602A true DK200000602A (da) | 2000-10-14 |
Family
ID=27383840
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK200000602A DK200000602A (da) | 1999-04-13 | 2000-04-11 | Ny fremgangsåde til behandling |
| DK200000133U DK200000133U3 (da) | 1999-04-13 | 2000-04-11 | Ny farmaceutisk formulering |
| DK00303033T DK1044680T3 (da) | 1999-04-13 | 2000-04-11 | Hidtil ukendt behandlingsmetode med et højt dosisregimen af amoxycillin og kaliumclavulanat |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK200000133U DK200000133U3 (da) | 1999-04-13 | 2000-04-11 | Ny farmaceutisk formulering |
| DK00303033T DK1044680T3 (da) | 1999-04-13 | 2000-04-11 | Hidtil ukendt behandlingsmetode med et højt dosisregimen af amoxycillin og kaliumclavulanat |
Country Status (45)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9407386D0 (en) | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
| GB9408117D0 (en) * | 1994-04-23 | 1994-06-15 | Smithkline Beecham Corp | Pharmaceutical formulations |
| BR9610396A (pt) * | 1995-09-07 | 1999-07-06 | Smithkline Beecham Corp | Formulação farmacêutica |
| SE9802973D0 (sv) | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
| US6878386B1 (en) | 1999-04-13 | 2005-04-12 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate |
| US7250176B1 (en) | 1999-04-13 | 2007-07-31 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection |
| US6294199B1 (en) | 1999-04-13 | 2001-09-25 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising administering amoxycillin |
| US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
| US6756057B2 (en) | 2000-10-12 | 2004-06-29 | Beecham Pharmaceuticals (Pte) Limited | Amoxicillin and potassium clavulanate dosage form |
| WO2002030392A2 (en) * | 2000-10-12 | 2002-04-18 | Beecham Pharmaceuticals (Pte) Limited | Formulation containing amoxicillin |
| US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
| US20030035839A1 (en) * | 2001-05-15 | 2003-02-20 | Peirce Management, Llc | Pharmaceutical composition for both intraoral and oral administration |
| WO2003004030A1 (en) | 2001-07-06 | 2003-01-16 | Endo Pharmaceuticals, Inc. | Oxymorphone controlled release formulations |
| GB0117618D0 (en) * | 2001-07-19 | 2001-09-12 | Phoqus Ltd | Pharmaceutical dosage form |
| US6863901B2 (en) | 2001-11-30 | 2005-03-08 | Collegium Pharmaceutical, Inc. | Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration |
| US6827946B2 (en) | 2001-12-05 | 2004-12-07 | Collegium Pharmaceutical, Inc. | Compositions containing both sedative and non-sedative antihistamines |
| EP1492511B3 (de) | 2002-04-09 | 2012-05-02 | Flamel Technologies | Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen |
| EP1499303A4 (de) * | 2002-04-10 | 2007-07-25 | Fred H Miller | Mehrphasiges mehrkompartment kapselsystem |
| US20050042289A1 (en) * | 2003-04-29 | 2005-02-24 | Yamanouchi Pharma Technologies, Inc. | Tablets and methods for modified release of hydrophylic and other active agents |
| AU2004264356B2 (en) | 2003-08-12 | 2011-01-27 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| EP1541129A1 (de) * | 2003-12-12 | 2005-06-15 | Cimex AG | Amoxycillin und Clavulanat enthaltende pharmazeutische Brauseformulierung |
| EP1750717B1 (de) * | 2004-02-11 | 2017-07-19 | Rubicon Research Private Limited | Pharmazeutische zusammensetzungen mit kontrollierter freisetzung und verbesserter bioverfügbarkeit |
| WO2005099672A1 (en) * | 2004-04-13 | 2005-10-27 | Ranbaxy Laboratories Limited | A modified release pharmaceutical formulation comprising amoxicillin and clavulanate |
| EP1880716A1 (de) * | 2006-07-19 | 2008-01-23 | Sandoz AG | Kit enthaltend einen säureempfindlichen pharmazeutischen Wirkstoff sowie einen säurestabilen pharmazeutischen Wirkstoff |
| MX2009003771A (es) * | 2006-10-10 | 2009-07-22 | Penwest Pharmaceuticals Co | Formulaciones robustas de liberacion sostenida. |
| TR200909787A2 (tr) | 2009-12-25 | 2011-07-21 | Bi̇lgi̇ç Mahmut | Üçüncü kuşak bir sefalosporin ve klavulanik asit içeren farmasötik formülasyonlar. |
| TR201000688A2 (tr) | 2010-01-29 | 2011-08-22 | B�Lg�� Mahmut | Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar. |
| TR201000687A1 (tr) | 2010-01-29 | 2011-08-22 | Bi̇lgi̇ç Mahmut | Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar |
| TR201000686A1 (tr) | 2010-01-29 | 2011-08-22 | B�Lg�� Mahmut | Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@ |
| CA2981759C (en) | 2015-04-07 | 2021-10-12 | Church & Dwight Co., Inc. | Multicomponent gummy compositions with soft core |
| CN109394718B (zh) * | 2018-11-15 | 2021-04-27 | 石药集团中诺药业（石家庄）有限公司 | 一种阿莫西林分散片及其制备方法 |
| CN110051637A (zh) * | 2019-05-21 | 2019-07-26 | 葵花药业集团北京药物研究院有限公司 | 阿莫西林克拉维酸钾制剂及其制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2964817D1 (en) * | 1978-09-06 | 1983-03-24 | Beecham Group Plc | Pharmaceutical compositions containing two beta-lactam derivatives |
| IL58461A0 (en) * | 1978-10-27 | 1980-01-31 | Beecham Group Ltd | Intramammary compositions comprising a clavulanic acid salt |
| FR2470599A1 (fr) * | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
| GB9007945D0 (en) * | 1990-04-07 | 1990-06-06 | Beecham Group Plc | Pharmaceutical formulation |
| GB9109862D0 (en) * | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
| IT1255522B (it) * | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
| EP1034784A3 (de) * | 1993-01-22 | 2001-06-27 | Smithkline Beecham Plc | Pharmazeutische Zusammensetzungen, die Clavulansäure und ein antibakterielle Mittel enthalten |
| GB9311030D0 (en) * | 1993-05-28 | 1993-07-14 | Smithkline Beecham Corp | Pharmaceutical formulations |
| IL109770A0 (en) * | 1993-05-29 | 1994-11-28 | Smithkline Beecham Corp | Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby |
| GB9402203D0 (en) * | 1994-02-04 | 1994-03-30 | Smithkline Beecham Plc | Pharmaceutical formulation |
| GB9407386D0 (en) * | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
| GB9408117D0 (en) * | 1994-04-23 | 1994-06-15 | Smithkline Beecham Corp | Pharmaceutical formulations |
| ITMI941169A1 (it) * | 1994-06-06 | 1995-12-06 | Smithkline Beecham Farma | Formulazioni farmaceutiche |
| GB9416600D0 (en) * | 1994-08-17 | 1994-10-12 | Smithkline Beecham Plc | Pharmaceutical formulation |
| GB9416599D0 (en) * | 1994-08-17 | 1994-10-12 | Smithkline Beecham Plc | Pharmaceutical formulation |
| BR9610396A (pt) * | 1995-09-07 | 1999-07-06 | Smithkline Beecham Corp | Formulação farmacêutica |
| GB9616536D0 (en) * | 1996-08-06 | 1996-09-25 | Quadrant Holdings Cambridge | Co-amoxiclav dosage form |
| PL334976A1 (en) * | 1997-02-14 | 2000-03-27 | Smithkline Beecham Lab | Pharmaceutic preparations containing amoxycyclin and clavulate |
| CA2283467A1 (en) * | 1997-03-11 | 1998-09-17 | Almag Al | Process and apparatus for coating metals |
| SE9700885D0 (sv) * | 1997-03-12 | 1997-03-12 | Astra Ab | New pharmaceutical formulation |
| CA2282531A1 (en) * | 1997-03-25 | 1998-10-01 | Takeda Chemical Industries, Ltd. | Gastrointestinal mucosa-adherent pharmaceutical composition |
| JP3746901B2 (ja) * | 1997-10-15 | 2006-02-22 | ユニ・チャーム株式会社 | 開閉自在容器 |
| GB9815532D0 (en) * | 1998-07-17 | 1998-09-16 | Lek Pharmaceutical & Cvhemical | Pharmaceutical suspension formulation |
| GB9818927D0 (en) * | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Pharmaceutical formulation |
| US6225304B1 (en) * | 1999-02-17 | 2001-05-01 | Pharmaceutical Solutions, Inc. | Soluble forms of amoxicillin and treatment of animals |
-
2000
- 2000-04-11 AT AT00303033T patent/ATE242629T1/de active
- 2000-04-11 DE DE60003255T patent/DE60003255T2/de not_active Expired - Lifetime
- 2000-04-11 EP EP02078928A patent/EP1269997A1/de not_active Withdrawn
- 2000-04-11 GR GR20000100122A patent/GR1003560B/el unknown
- 2000-04-11 IL IL14558000A patent/IL145580A0/xx active IP Right Grant
- 2000-04-11 AP APAP/P/2001/002284A patent/AP1806A/en active
- 2000-04-11 CO CO00026419A patent/CO5170471A1/es not_active Application Discontinuation
- 2000-04-11 ES ES00303033T patent/ES2202004T3/es not_active Expired - Lifetime
- 2000-04-11 DZ DZ003150A patent/DZ3150A1/xx active
- 2000-04-11 NL NL1014915A patent/NL1014915C2/nl not_active IP Right Cessation
- 2000-04-11 NZ NZ514575A patent/NZ514575A/en not_active IP Right Cessation
- 2000-04-11 SI SI200000097A patent/SI20304A/sl not_active IP Right Cessation
- 2000-04-11 PL PL339591A patent/PL197448B1/pl unknown
- 2000-04-11 FR FR0004631A patent/FR2792198A1/fr active Pending
- 2000-04-11 PT PT00303033T patent/PT1044680E/pt unknown
- 2000-04-11 BG BG104329A patent/BG65006B1/bg unknown
- 2000-04-11 RO ROA200000399A patent/RO120817B1/ro unknown
- 2000-04-11 AU AU57020/00A patent/AU767177B2/en not_active Expired
- 2000-04-11 WO PCT/IB2000/000992 patent/WO2000061116A2/en active Application Filing
- 2000-04-11 DE DE10017883A patent/DE10017883A1/de not_active Withdrawn
- 2000-04-11 CN CNB008086737A patent/CN100382782C/zh not_active Expired - Lifetime
- 2000-04-11 KR KR1020017012988A patent/KR100634937B1/ko not_active IP Right Cessation
- 2000-04-11 EP EP02078927A patent/EP1270005A3/de not_active Withdrawn
- 2000-04-11 MY MYPI20001509A patent/MY119953A/en unknown
- 2000-04-11 SE SE0001330A patent/SE0001330L/xx not_active Application Discontinuation
- 2000-04-11 CZ CZ20001311A patent/CZ298801B6/cs not_active IP Right Cessation
- 2000-04-11 ES ES200000935A patent/ES2190692B1/es not_active Withdrawn - After Issue
- 2000-04-11 DK DK200000602A patent/DK200000602A/da not_active Application Discontinuation
- 2000-04-11 OA OA1200100257A patent/OA11926A/en unknown
- 2000-04-11 DK DK200000133U patent/DK200000133U3/da not_active IP Right Cessation
- 2000-04-11 EP EP00303033A patent/EP1044680B1/de not_active Expired - Lifetime
- 2000-04-11 MX MXPA01010377A patent/MXPA01010377A/es active IP Right Grant
- 2000-04-11 DK DK00303033T patent/DK1044680T3/da active
- 2000-04-11 SK SK534-2000A patent/SK285140B6/sk not_active IP Right Cessation
- 2000-04-11 HU HU0001471A patent/HU229097B1/hu unknown
- 2000-04-11 EA EA200101075A patent/EA004310B1/ru not_active IP Right Cessation
- 2000-04-11 BE BE2000/0255A patent/BE1013309A5/fr not_active IP Right Cessation
- 2000-04-11 FI FI20000863A patent/FI20000863A/fi unknown
- 2000-04-11 BE BE00/0256A patent/BE1012733A6/fr not_active IP Right Cessation
- 2000-04-11 NO NO20001870A patent/NO329694B1/no not_active IP Right Cessation
- 2000-04-11 AR ARP000101657A patent/AR031068A1/es not_active Application Discontinuation
- 2000-04-11 GB GB0008923A patent/GB2351661B/en not_active Revoked
- 2000-04-11 JP JP2000610449A patent/JP4880125B2/ja not_active Expired - Lifetime
- 2000-04-11 TR TR2001/02963T patent/TR200102963T2/xx unknown
- 2000-04-11 PE PE2000000332A patent/PE20010053A1/es not_active Application Discontinuation
- 2000-04-11 IT IT2000MI000788A patent/ITMI20000788A1/it unknown
- 2000-04-11 SI SI200030183T patent/SI1044680T1/xx unknown
- 2000-04-11 TW TW089106937A patent/TWI235067B/zh not_active IP Right Cessation
- 2000-04-11 NL NL1014914A patent/NL1014914C1/nl not_active IP Right Cessation
- 2000-04-11 IE IE20000271A patent/IE20000271A1/en not_active IP Right Cessation
- 2000-04-11 AT AT0027900U patent/AT4327U1/de not_active IP Right Cessation
- 2000-04-11 FI FI20000164U patent/FI4823U1/fi active
- 2000-04-11 CA CA002366304A patent/CA2366304C/en not_active Expired - Lifetime
- 2000-04-11 PT PT102450A patent/PT102450B/pt active IP Right Grant
- 2000-04-11 DE DE20006626U patent/DE20006626U1/de not_active Expired - Lifetime
- 2000-04-11 EP EP02078926A patent/EP1269996A1/de not_active Withdrawn
- 2000-04-11 BR BRPI0009719A patent/BRPI0009719B8/pt not_active IP Right Cessation
-
2001
- 2001-03-21 HK HK01102048A patent/HK1032741A1/xx not_active IP Right Cessation
- 2001-09-24 IL IL145580A patent/IL145580A/en not_active IP Right Cessation
- 2001-10-12 MA MA26356A patent/MA25352A1/fr unknown
-
2011
- 2011-07-22 JP JP2011161132A patent/JP2011256180A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK200000602A (da) | Ny fremgangsåde til behandling | |
| JP2002541187A5 (de) | ||
| US6673369B2 (en) | Controlled release formulation | |
| US6756057B2 (en) | Amoxicillin and potassium clavulanate dosage form | |
| US7011849B2 (en) | Second release phase formulation | |
| EP1246668B1 (de) | Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne | |
| WO2003047519A3 (en) | 'compressed annular tablet with molded triturate tablet for oral and intraoral' | |
| CA2182004C (en) | Film coated tablet of paracetamol and domperidone | |
| CA2411882A1 (en) | Solid valsartan pharmaceutical compositions | |
| US7704526B2 (en) | Sustained release composition for oral administration of drugs | |
| US7759368B2 (en) | Sustained release composition for oral administration of niacin | |
| JP2013523834A (ja) | ｐＨの影響を改善したアタザナビル硫酸塩製剤 | |
| US20060002997A1 (en) | Nitrofurantoin controlled release dosage form | |
| EP1512394A1 (de) | Universelle Zusammensetzung zur kontrollierten Wirkstoffabgabe enthaltend Chitosan | |
| WO2011093829A1 (en) | Effervescent formulations comprising cefixime and clavulanic acid as active agents | |
| US20050053657A1 (en) | Controlled release formulation of clarithromycin or tinidazol | |
| DE60117712D1 (de) | Pharmazeutische zusammensetzung für die kontrollierte freisetzung eines beta-lactam-antibiotikums | |
| KR20010006835A (ko) | 경구용 속붕해정 | |
| EP1948132A1 (de) | Zolpidemtabletten | |
| EP2471521A1 (de) | Doppelschichtige, osmosepumpengesteuerte freisetzungstablette von bicyclol und herstellungsverfahren dafür | |
| MXPA06010805A (es) | Formulacion de claritromicina de libracion prolongada. | |
| AU2005227095A1 (en) | Prolonged-release compositions comprising torasemide and a matrix-forming polymer | |
| WO2005067895A1 (en) | Controlled release pharmaceutical compositions | |
| WO2016130094A1 (en) | A pharmaceutical composition containing ibuprofen, pseudoephedrine and vitamin c | |
| RU2603469C2 (ru) | Таблетка с контролируемым высвобождением для перорального введения и способ ее приготовления |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AHS | Application shelved for other reasons than non-payment |